CN102406623A - 一种尼索地平控释片剂及其制备方法 - Google Patents
一种尼索地平控释片剂及其制备方法 Download PDFInfo
- Publication number
- CN102406623A CN102406623A CN2010102918240A CN201010291824A CN102406623A CN 102406623 A CN102406623 A CN 102406623A CN 2010102918240 A CN2010102918240 A CN 2010102918240A CN 201010291824 A CN201010291824 A CN 201010291824A CN 102406623 A CN102406623 A CN 102406623A
- Authority
- CN
- China
- Prior art keywords
- nisoldipine
- controlled release
- release tablet
- sodium
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 title claims abstract description 151
- 229960000227 nisoldipine Drugs 0.000 title claims abstract description 149
- 238000002360 preparation method Methods 0.000 title claims abstract description 54
- 238000013270 controlled release Methods 0.000 title claims abstract description 45
- 239000000463 material Substances 0.000 claims abstract description 20
- 230000001419 dependent effect Effects 0.000 claims abstract description 17
- 239000004094 surface-active agent Substances 0.000 claims abstract description 16
- 239000000314 lubricant Substances 0.000 claims abstract description 12
- 239000000945 filler Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 87
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 87
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 71
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 70
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 61
- 230000008569 process Effects 0.000 claims description 44
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 42
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 42
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 41
- 229960003943 hypromellose Drugs 0.000 claims description 41
- 239000008187 granular material Substances 0.000 claims description 37
- 235000019359 magnesium stearate Nutrition 0.000 claims description 35
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 34
- 239000000741 silica gel Substances 0.000 claims description 34
- 229910002027 silica gel Inorganic materials 0.000 claims description 34
- 229920000178 Acrylic resin Polymers 0.000 claims description 31
- 239000004925 Acrylic resin Substances 0.000 claims description 31
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 27
- 239000008101 lactose Substances 0.000 claims description 26
- 239000002671 adjuvant Substances 0.000 claims description 23
- -1 polyoxyethylene Polymers 0.000 claims description 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 14
- 238000009826 distribution Methods 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 239000011253 protective coating Substances 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 238000007908 dry granulation Methods 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 5
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- 229940075529 glyceryl stearate Drugs 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 claims description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 2
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 claims description 2
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 2
- 239000010410 layer Substances 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000002356 single layer Substances 0.000 abstract description 3
- 239000004520 water soluble gel Substances 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 description 35
- 239000007787 solid Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 239000003814 drug Substances 0.000 description 16
- 238000004090 dissolution Methods 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000000337 buffer salt Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000003405 delayed action preparation Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 5
- 101000692878 Homo sapiens Regulator of MON1-CCZ1 complex Proteins 0.000 description 5
- 102100026436 Regulator of MON1-CCZ1 complex Human genes 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 102000008482 12E7 Antigen Human genes 0.000 description 4
- 108010020567 12E7 Antigen Proteins 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229960001597 nifedipine Drugs 0.000 description 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000000297 inotrophic effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940121792 Thiazide diuretic Drugs 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000007561 laser diffraction method Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- RYDFXSRVZBYYJV-TYYBGVCCSA-N (e)-but-2-enedioic acid;sodium Chemical compound [Na].OC(=O)\C=C\C(O)=O RYDFXSRVZBYYJV-TYYBGVCCSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 1
- 239000002866 dihydropyridine calcium channel blocker Substances 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000001599 direct drying Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940035718 sular Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
f2 | 处方D | 处方E | 处方F | 处方G | 处方H |
pH6.8释放 | 69 | 63 | 65 | 56 | 56 |
pH1.2释放 | 64 | 71 | 66 | 58 | 55 |
f2 | 处方L | 处方M | 处方N |
pH1.2释放 | 54 | 53 | 67 |
f2 | 处方O | 处方P |
pH6.8释放 | 59 | 67 |
pH1.2释放 | 61 | 62 |
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010291824.0A CN102406623B (zh) | 2010-09-26 | 2010-09-26 | 一种尼索地平控释片剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010291824.0A CN102406623B (zh) | 2010-09-26 | 2010-09-26 | 一种尼索地平控释片剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102406623A true CN102406623A (zh) | 2012-04-11 |
CN102406623B CN102406623B (zh) | 2014-08-27 |
Family
ID=45909166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010291824.0A Active CN102406623B (zh) | 2010-09-26 | 2010-09-26 | 一种尼索地平控释片剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102406623B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013098831A2 (en) * | 2011-09-23 | 2013-07-04 | Emcure Pharmaceuticals Limited | Controlled release formulations of nisoldipine |
CN103381268A (zh) * | 2012-05-04 | 2013-11-06 | 江苏豪森药业股份有限公司 | 包含质子泵抑制剂的固体药物组合物 |
CN108347990A (zh) * | 2015-10-16 | 2018-07-31 | 诺维克斯科学私人有限公司 | 维生素c和锌片剂的稳定组合物 |
CN109364037A (zh) * | 2018-12-11 | 2019-02-22 | 湖北舒邦药业有限公司 | 拉呋替丁片剂及其制备方法 |
CN110604722A (zh) * | 2019-09-19 | 2019-12-24 | 山东创新药物研发有限公司 | 一种塞来昔布的固体分散方法及塞来昔布胶囊的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552323A (zh) * | 2003-12-19 | 2004-12-08 | 沈阳药科大学 | 尼索地平单层渗透泵控释片 |
CN101257946A (zh) * | 2005-07-06 | 2008-09-03 | 拜耳医药保健股份公司 | 包含硝苯地平和/或尼索地平和血管紧张素ⅱ拮抗剂的活性成分组合的药物剂型 |
CN101516352A (zh) * | 2006-08-30 | 2009-08-26 | 雅戈泰克股份公司 | 包含尼索地平的控释固体口服制剂 |
-
2010
- 2010-09-26 CN CN201010291824.0A patent/CN102406623B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552323A (zh) * | 2003-12-19 | 2004-12-08 | 沈阳药科大学 | 尼索地平单层渗透泵控释片 |
CN101257946A (zh) * | 2005-07-06 | 2008-09-03 | 拜耳医药保健股份公司 | 包含硝苯地平和/或尼索地平和血管紧张素ⅱ拮抗剂的活性成分组合的药物剂型 |
CN101516352A (zh) * | 2006-08-30 | 2009-08-26 | 雅戈泰克股份公司 | 包含尼索地平的控释固体口服制剂 |
Non-Patent Citations (2)
Title |
---|
杨春光等: "尼索地平缓释片处方工艺的研究", 《中国新药杂志》, vol. 13, no. 10, 30 October 2004 (2004-10-30), pages 904 - 906 * |
黄胜炎: "改善口服固体制剂溶出度的方法", 《中国医药工业杂志》, vol. 22, no. 3, 1 April 1991 (1991-04-01), pages 131 - 135 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013098831A2 (en) * | 2011-09-23 | 2013-07-04 | Emcure Pharmaceuticals Limited | Controlled release formulations of nisoldipine |
WO2013098831A3 (en) * | 2011-09-23 | 2014-10-02 | Emcure Pharmaceuticals Limited | Controlled release formulations of nisoldipine |
CN103381268A (zh) * | 2012-05-04 | 2013-11-06 | 江苏豪森药业股份有限公司 | 包含质子泵抑制剂的固体药物组合物 |
CN103381268B (zh) * | 2012-05-04 | 2017-12-08 | 江苏豪森药业集团有限公司 | 包含质子泵抑制剂的固体药物组合物 |
CN108347990A (zh) * | 2015-10-16 | 2018-07-31 | 诺维克斯科学私人有限公司 | 维生素c和锌片剂的稳定组合物 |
CN109364037A (zh) * | 2018-12-11 | 2019-02-22 | 湖北舒邦药业有限公司 | 拉呋替丁片剂及其制备方法 |
CN110604722A (zh) * | 2019-09-19 | 2019-12-24 | 山东创新药物研发有限公司 | 一种塞来昔布的固体分散方法及塞来昔布胶囊的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102406623B (zh) | 2014-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2448406B1 (en) | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use | |
CN102325526B (zh) | 延长释放的药物制剂 | |
CN102406623B (zh) | 一种尼索地平控释片剂及其制备方法 | |
CA2850706C (en) | Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound | |
CN105682648A (zh) | 用于以低的日剂量施用的含富马酸二甲酯的药物组合物 | |
KR20010082251A (ko) | 서방성 입자 | |
SA515360425B1 (ar) | صيغ للإعطاء بالفم من ديفيرازيروكس | |
CN1969849A (zh) | 一种稳定的含有匹伐他汀钙的药物组合物及其制备方法 | |
CN102949359B (zh) | 一种头孢妥仑匹酯片及其制备方法 | |
CN101370484B (zh) | 含有厄贝沙坦的固体药物组合物 | |
CN102091053B (zh) | 一种颗粒组合控释片 | |
Yang et al. | A novel pH-dependent gradient-release delivery system for nitrendipine: I. Manufacturing, evaluation in vitro and bioavailability in healthy dogs | |
CN102526748B (zh) | 含有缬沙坦、氢氯噻嗪和苯磺酸氨氯地平的口服片剂 | |
CN118056565A (zh) | 含有氢溴酸伏硫西汀的药物组合物及其制备方法 | |
CN102266292B (zh) | 骨架型双氯芬酸钾缓释微丸胶囊及其生产工艺 | |
JP6775155B2 (ja) | 錠剤 | |
CN106309395A (zh) | 一种他克莫司缓释片及其制备方法 | |
US20060063832A1 (en) | Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof | |
CN103655470A (zh) | 一种度他雄胺自微乳组合物及其制备方法 | |
CN102670603B (zh) | 含有坎地沙坦酯和苯磺酸氨氯地平的口服片剂及其制备方法 | |
CN101087612A (zh) | 水溶性差的活性物质的口服速释制剂 | |
CN102499929B (zh) | 42-(二甲基亚膦酰)雷帕霉素固体组合物及其包衣方法 | |
EP3035919B1 (en) | Duloxetine enteric coated tablet | |
CN106983752A (zh) | 一种缬沙坦氢氯噻嗪胶囊的制备方法 | |
CZ295584B6 (cs) | Farmaceutická kompozice obsahující jako účinnou látku platinový komplex a způsob výroby této kompozice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 201203, Pudong New Area Zhangjiang hi tech park, Copernicus Lou, No. 2, building 150, Shanghai Applicant after: SHANGHAI SUNTECH PHARMACEUTICAL CO., LTD. Applicant after: Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd. Address before: 201203 Shanghai city Pudong New Area libing Road No. 306 Applicant before: Shanghai Fosun Pushi Pharmaceutical Technology Co., Ltd. Applicant before: Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: SHANGHAI FOSUN PUSHI PHARMACEUTICAL TECHNOLOGY CO., LTD. TO: SHANGHAI SUN-TECH PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 201210 Zhang Heng Road, 1999, China (Shanghai) free trade test area, No. 1999 Co-patentee after: Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd. Patentee after: Shanghai Double Star Thai Pharmaceutical Technology Co., Ltd. Address before: 201203, Pudong New Area Zhangjiang hi tech park, Copernicus Lou, No. 2, building 150, Shanghai Co-patentee before: Shanghai Fosun Pharmaceutical (Group) Limited by Share Ltd. Patentee before: SHANGHAI SUNTECH PHARMACEUTICAL CO., LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210421 Address after: 201210 building 7, 1999 zhangheng Road, Pudong New Area pilot Free Trade Zone, Shanghai Patentee after: SHANGHAI FOSUN XINGTAI PHARMA TECHNOLOGY Co.,Ltd. Patentee after: SHANGHAI FOSUN PHARMACEUTICAL (Group) Co.,Ltd. Patentee after: JIANGSU WANBANG BIOPHARMACEUTICAL GROUP Co.,Ltd. Address before: 201210 China (Shanghai) free trade pilot area, 7 Zhang Heng Road, 1999 Patentee before: SHANGHAI FOSUN XINGTAI PHARMA TECHNOLOGY Co.,Ltd. Patentee before: SHANGHAI FOSUN PHARMACEUTICAL (Group) Co.,Ltd. |